Skip to content
OpenCapital
Get started

Journey Medical Corporation DERM Cash & Equivalents

Cash & Equivalents at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$1.31B+13.4%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$11.01M-27.1%
PTH
Pelthos Therapeutics Inc.PTHS
$31.98M+24,250%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$35.07M-34.7%
HRO
HarrowHROW
$94.64M+41.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$755.86M+30.2%

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M—
Free cash flow-$6.0M—

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S3×+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%—
Net margin-14.8%—
FCF margin-43%—

Returns & leverage

See full
Return on equity-36.6%—
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's cash & equivalents?
Journey Medical Corporation (DERM) reported cash & equivalents of $27.22M in Q1 2026.
How has Journey Medical Corporation's cash & equivalents changed year-over-year?
Journey Medical Corporation's cash & equivalents increased by 29.2% year-over-year, from $21.07M to $27.22M.
What is the long-term trend for Journey Medical Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Journey Medical Corporation's cash & equivalents has grown at a 23.9% compound annual growth rate (CAGR), from $8.25M to $24.09M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.